Biostem Technologies (NASDAQ:BSEM) Issues Earnings Results, Misses Estimates By $0.21 EPS

Biostem Technologies (NASDAQ:BSEM) posted its quarterly earnings results on Thursday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.21), reports. The firm had revenue of $7.64 million for the quarter, compared to analysts’ expectations of $7.17 million. Biostem Technologies had a negative net margin of 76.02% and a negative return on equity of 60.22%.

Here are the key takeaways from Biostem Technologies’ conference call:

• BioStem raised the low end of its 2026 revenue guidance to $28 million–$29 million and expects sequential hospital-channel growth in Q4. Hospital revenue rose 2% sequentially to $6.8 million, although total Q3 revenue declined to $7.6 million from $7.9 million in Q2.
• The company is finalizing a cost-reduction plan expected to lower annualized cash operating expenses by $10 million–$12 million, with full benefits expected to begin in Q1 2027. It also expects to move Neox and Clarix manufacturing in-house in the first half of 2027, which management believes could lift gross margins by 10–15 percentage points over time.
• Commercial indicators included a 14% sequential increase in accounts buying at least two product lines and growth of more than 40% in accounts buying three or more. VENDAJE was added to agreements with two major GPOs, expanding access through existing hospital contracting channels.
• Q3 gross margin fell to 56% from 61% in Q2, and the adjusted EBITDA loss widened to $6.4 million from $4.6 million. Cash used in operating activities increased to $8.8 million, leaving $1 million in cash at quarter-end.
• BioStem is pursuing additional financing and working-capital options, and discussions to restructure an outstanding BioTissue clearance payment remain ongoing. The company has not drawn on its $40 million equity facility, but it may not be available until early April 2027 absent a waiver, and future use could dilute shareholders.

Biostem Technologies Trading Down 12.7%

NASDAQ:BSEM traded down $0.17 during mid-day trading on Friday, hitting $1.14. The company had a trading volume of 166,670 shares, compared to its average volume of 111,853. The business has a fifty day simple moving average of $2.63 and a 200-day simple moving average of $3.99. Biostem Technologies has a 1 year low of $1.00 and a 1 year high of $8.40. The firm has a market capitalization of $21.19 million, a price-to-earnings ratio of -0.71 and a beta of 0.36.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BSEM shares. Wall Street Zen raised Biostem Technologies to a “sell” rating in a research note on Saturday, September 5th. Weiss Ratings initiated coverage on Biostem Technologies in a report on Wednesday, August 19th. They set a “sell (d-)” rating for the company. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.00.

About Biostem Technologies

BioStem Technologies, Inc. is a biotechnology company focused on regenerative medicine and biologic tissue products. The company develops, manufactures and commercializes human tissue allografts intended to support wound care, tissue repair and other medical applications. Its product portfolio includes placental- and birth-tissue-derived products, such as amniotic membrane and umbilical cord allografts. These products are marketed for use by healthcare providers in areas including wound management, surgical procedures and related regenerative-care applications.